The Life Sciences team advised CRISPR Therapeutics AG (Nasdaq: CRSP) on the completion of its underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares (which closed on December 2), of an aggregate of 4,887,500 common shares at $64.50 per share, for aggregate gross proceeds of approximately $315.2 million, before deducting underwriting discounts and commissions and estimated offering expenses. The underwriters have a 30-day option to purchase up to an additional 637,500 common shares at the public offering price less the underwriting discount.
CRISPR Therapeutics AG is a biopharmaceutical company and a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
The Goodwin team was led by Robert Puopolo, Seo Salimi, John Mei, Sarah Smith, Carly Ward and Navid Wheeler (Corporate), Stephanie Philbin (Regulatory), Daniel Karelitz and Alexander Plaum (Tax), Brian Fairchild (IP) and Ettore Santucci (Capital Markets), with invaluable assistance from paralegal Pamela Finan.
For more information on the offering, please read the press release.